Severe abdominal pain , particularly if it is constant, worsening, or accompanied by fever, should be evaluated urgently
The SELECT trial, published in 2023, demonstrated that semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease but without diabetes
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Tirzepatide Compounded Tirzepatide promotes offers powerful support for achieving lasting weight loss GLP-1s GLP-1 injections aid weight loss by curbing appetite and improving blood sugar control